Compare CAL & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAL | ORKA |
|---|---|---|
| Founded | 1878 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 432.0M | 5.6B |
| IPO Year | 1994 | 1997 |
| Metric | CAL | ORKA |
|---|---|---|
| Price | $12.33 | $82.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 12 |
| Target Price | $15.00 | ★ $92.50 |
| AVG Volume (30 Days) | 547.9K | ★ 808.4K |
| Earning Date | 05-28-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.13% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.14 | N/A |
| Revenue | ★ $85,513,000.00 | N/A |
| Revenue This Year | $5.19 | N/A |
| Revenue Next Year | $2.45 | N/A |
| P/E Ratio | $5.86 | ★ N/A |
| Revenue Growth | ★ 0.46 | N/A |
| 52 Week Low | $8.80 | $18.19 |
| 52 Week High | $15.04 | $115.52 |
| Indicator | CAL | ORKA |
|---|---|---|
| Relative Strength Index (RSI) | 48.02 | 33.54 |
| Support Level | $11.54 | $29.45 |
| Resistance Level | $14.15 | $97.45 |
| Average True Range (ATR) | 0.53 | 4.60 |
| MACD | 0.06 | -1.12 |
| Stochastic Oscillator | 57.94 | 7.73 |
Caleres Inc is a footwear company that operates retail shoe stores and e-commerce websites, and designs, develops, sources, manufactures, and distributes footwear for people of all ages. The Company's business operations are organized into two reportable segments - Famous Footwear and Brand Portfolio. The Famous Footwear segment is comprised of its Famous Footwear retail stores, famousfootwear.com, and famousfootwear.ca. The Brand Portfolio segment offers retailers and consumers a cultivated portfolio of known brands. This segment is comprised of wholesale operations that designs, develops, sources, manufactures, markets and distributes branded, licensed and private-label footwear. Geographically, the company generates the majority of its revenue from Domestic operations.
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.